News Releases

Trudhesa ® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc.

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W.

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023,

New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant Use of Trudhesa with Triptans and Preventative CGRP, Erenumab, Were

H. Stewart Parker Departing from Board SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of

Highlights Include Multiple Presentations Addressing Safety and Efficacy of Trudhesa SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet

Trudhesa ® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24,

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth Momentum Continues, with 58 Percent Increase in New Prescriptions from  Q2 2022 to